Latest PBLS news

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Wed, 16 Sep 2026 17:51:37 -0400

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · Tue, 01 Sep 2026 07:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D.

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

GlobeNewsWire · Tue, 25 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Seeking Alpha · Fri, 14 Aug 2026 10:36:55 -0400

Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · Thu, 13 Aug 2026 07:00:00 -0400

Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors

Primary Markets Group June 2026 U.S. IPO Update

Seeking Alpha · Fri, 17 Jul 2026 03:35:00 -0400

The U.S. IPO market shattered records in June 2026, propelled by the ‘out of this world' debut of Space Exploration Technologies Corp. The month saw 19 IPOs raising a staggering $97.9 billion, which was a dramatic increase from the $13.1 billion raised across 12 deals in May and the $4.2 billion across 10 IPOs in June 2025. Looking at pricing performance, the best first-day performance came from healthcare firm Parabilis Medicines, Inc., which increased 58.0% after pricing its offering above its initial filing range.

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga · Mon, 06 Jul 2026 07:11:19 -0400

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Market information is provided for research and visualization and is not investment advice.